Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is a phase IIa human clinical study, in which 60 patients with intracerebral hemorrhage (ICH) at basal ganglion or thalamus within 6 h after onset will be enrolled. Patients will be randomly assigned as treatment group or control group as 1:1 distribution. Early initiation of celecoxib within 6 h after ICH and treatment for 21 days will be performed. The safety will be evaluated by drug adverse effects. The efficacy will be assessed by hematoma expansion, brain edema, and 3-month modified Rankin scale.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study

NCT00526214

Intracerebral Hemorrhage

COMPLETED NA

Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial

NCT06899464

Intracerebral Hemorrhage Hemorrhagic Stroke, Intracerebral Hemorrhagic Stroke +1 more

NOT_YET_RECRUITING PHASE4

Colchicine for the Reduction of Dependency and Vascular Events After an Acute Intracerebral Hemorrhage

NCT06587737

Colchicine ICH - Intracerebral Hemorrhage Stroke +1 more

NOT_YET_RECRUITING PHASE3

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

NCT06763055

Intracerebral Hemorrhage Spontaneous Intracerebral Hemorrhage Supratentorial Intracerebral Haemorrhage +2 more

RECRUITING PHASE3

Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage

NCT07305896

Intracerebral Hemorrhage

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A phase IIa human clinical trial will be performed to clarify the safety and efficacy of using usual dose of celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH. Totally 60 patients will be enrolled prospectively, and the case number was estimated by statistical methods for the percentage of participants with increased perihematomal edema volume shown in the previous clinical trial (Lee et al., 2013) (estimated by G-power software, settings as: exact test, one sample test, α = 0.05, power = 0.95). Patients will be randomly assigned as treatment group or control group as 1:1 distribution.

Intervention: Celecoxib 200 mg per dose, started within 6 h after onset, then one dose per day for 21 days in the treatment group. The low dose of Celecoxib will be used to minimize the side effect of Celecoxib. No trial medication will be given for the control group. Pregnancy will be excluded at enrollment and prevented throughout the treatment period in female cases at reproductive ages.

Evaluations:

1. Brain CT:

1. Initial brain CT: for initial hematoma volume (length \* width \* height /2)
2. Brain CT on day 2 for final hematoma volume and hematoma expansion
3. Brain CT on day 7±1 for perihematomal edema and hematoma resolution
2. Neurological functions: NIHSS score, GCS score, modified Rankin scale (mRS) on day 1, 2, 7±2, 14±2, 21±2, and mRS at 3 months
3. Renal function (creatinine) on day 1, then once per week during day 2-7, day 8-14 and 15-21
4. Gastrointestinal bleeding evens within 21 days
5. Myocardial infarction evens within 21 days
6. Blood sampling on day 1, 7±2, and 21±2

Patient enrollment: If the patient's consciousness is not clear before the enrollment of this study, his (her) family can decide the enrollment for this patient. Once the patient regains his (her) consciousness, we will reconfirm with the patient about the enrollment of this study.

Data checks: The data recorded of this study will be double-checked for their accuracy and compared with predefined ranges to avoid typing error.

Plan for missing data: Missing data include those data which are reported as missing, unavailable, uninterpretable, or considered missing because of data inconsistency or out-of-range results. This study will try to minimize missing data by limiting the collection of data to essential information and minimizing the number of follow-up visits, develop a documentation of this study for the methods to screen the participants and the procedures to follow up, appropriate training for all personnel related to this study, and data will be reviewed as close to real-time as possible.

Statistical analysis plan: The continuous variables between Celecoxib group and control group will be compared using Mann-Whitney U test if these data are not with normal distribution, or t-test if these data are with normal distribution. Categorical data will be compared using Fisher's exact test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intracerebral Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Intracerebral hemorrhage

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Celebrex treatment arm

Celecoxib 200 mg/dose, started within 6 h after onset, then one dose per day for 21 days.

Group Type EXPERIMENTAL

Celecoxib 200mg

Intervention Type DRUG

Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH

Control arm

No trial medication will be given.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib 200mg

Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute ICH patients able to take the first dose within 6 hours after onset
* ICH location at basal ganglion or thalamus
* ICH volume \< 30 mL
* Normal renal function (creatinine \[Cr\] ≤ 1.3 mg/dL)
* No surgical indication
* Signed informed consent
* Consciousness clear or mild drowsiness
* Age 20-80 years old

Exclusion Criteria

* Allergy to celecoxib or other non-steroid anti-inflammatory drugs (NSAIDs)
* Post-coronary artery bypass graft (CABG) within 14 days
* Previous myocardial infarction
* Previous peptic ulcer disease
* Abnormal renal function (Cr \> 1.3 mg/dL)
* Surgery for this ICH
* Pregnancy or under breast feeding (If the female case is not sure about pregnancy, pregnancy test will be performed)
* Premorbid mRS \> or = 3
* Previous ICH not at basal ganglia or thalamus
* Coagulation abnormality (abnormal PT/PTT), or taking anticoagulant or antiplatelet
* Abnormal liver function (ALT \> 3x upper limit)
* History of severe bleeding event, requiring admission or blood transfusion
* History of stenting or valve replacement, requiring long-term using antithrombotics

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No